Rheumatoid Arthritis news from FierceBiotech
News
UCB files for Cimzia RA approval in Europe
UCB is taking its case to make Cimzia the first PEGylated anti-TNF biologic available to rheumatoid arthritis patients in front of the European Medicines Agency. Recently approved for Crohn's, Cimzia Read more...
Limerick raises $15M; Icahn offered $15B for Biogen; Neogen expands R&D
> Limerick BioPharma has ginned $11 million in venture funds and borrowed $4 million more to advance its work on the bioavailability of drugs. Arch Venture Partners, Sevin Rosen Funds and Altitude Read more...
Itero raises $21M; Immunicon files for Chapter 11; AVI cuts staff;
> San Mateo, CA-based Itero has formed a collaboration with India's Biological E. Limited and raised $21 million in a Series A. Read more...
SPOTLIGHT: Anesiva inks $114M licensing deal
Transcription Factor Therapeutics has licensed the worldwide rights to Anesiva's NF-kB Decoy program, which includes the clinical drug candidate Avrina. NF-kB Transcription Factor Decoy inhibits Read more...
Roche posts new data backing Actemra for RA
Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Researchers say their fifth Phase III trial demonstrated that the therapy inhibited structural Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
Nuon gets $27M to fund a mid-stage trial
Frazier Healthcare Ventures and Domain Associates have joined forces to lead a $27 million Series B for Nuon Therapeutics, a San Mateo, CA-based developer working on new therapies for autoimmune and Read more...
PBMs making big bucks off specialty drugs
Drugmakers aren't the only ones making money off the specialty drug trend. Specialty drugs, many of Read more...
GSK tests the miRNA waters with $600M deal
Further solidifying RNA's "next big thing" status, GlaxoSmithKline and Regulus Read more...
VC: Alimera land $30M in third round
Alimera land $30M in third round VENTURE CAPITALCOMPANY AMOUNT/ROUNDLEAD INVESTORSDESCRIPTIONAlimera SciencesAtlanta, Read more...
Get more Rheumatoid Arthritis coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends